TLP
BPMC

Tri Locum Partners’s Blueprint Medicines BPMC Stock Holding History

Tri Locum Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50,000
Closed -$4.43M – 24
2025
Q1 		$4.43M Buy
+50,000
New +$4.88M 2.27% 16
2021
Q1 		– Sell
-73,906
Closed -$8.29M – 42
2020
Q4 		$8.29M Buy
+73,906
New +$7.79M 3.01% 11

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Tri Locum Partners's BPMC Position: Q2 2025 in Review

Tri Locum Partners sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 50,000 shares — an estimated $4.43M sold.

Tri Locum Partners first reported a position in BPMC in Q4 2020 and held it in 2 quarters. The position peaked at $8.29M in Q4 2020. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Tri Locum Partners reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Tri Locum Partners sold 50,000 Blueprint Medicines shares in Q2 2025, an estimated $4.43M.
  • Tri Locum Partners first reported a position in Blueprint Medicines in Q4 2020 and held it in 2 quarters.
  • Tri Locum Partners's Blueprint Medicines position peaked at $8.29M in Q4 2020.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Tri Locum Partners's 13F filing for Q2 2025, filed 14 Aug 2025.